Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

Supermarket Discounts Promote Unhealthy Choices
Supermarket shoppers may be encouraged to buy sugar-filled, calorie-rich drinks by discounts and promotions, according to New Zealand research.
generic viagra online
Could Standard Treatment For Traumatic Brain Injury Be Wrong?
Traumatic brain injury not heart disease, stroke or cancer is the number one cause of death and disability in people under 45. Each year, some 1.5 million Americans, including soldiers, athletes, the elderly and children, sustain head injuries, and nearly half of them will be hospitalized and treated in an emergency room or intensive care unit.
News of the day
Aperio Introduces Industry's First Digital IHC Solution With Integrated Image Analysis For Quantification Of Breast Cancer
Aperio Technologies, Inc., (Aperio), a global leader in digital pathology for the healthcare and life sciences industry, is pleased to announce the launch of a digital pathology solution for Immunohistochemistry (IHC) designed specifically for the clinical market. Aperio"s digital IHC solution is the only commercially available FDA-cleared system allowing pathologists to run quantitative IHC image analysis while reading slides on a computer monitor.
Mental Health

Advaxis Engages The Numoda Corporation To Oversee Phase II Clinical Trials Of ADXS11-001

Advaxis, Incorporated (OTCBB: ADXS), has engaged the Numoda Corporation, a leading clinical trial and logistics management company, to oversee Phase II clinical activity with ADXS11-001 for the treatment of invasive cervix cancer and cervical intraepithelial neoplasia (CIN; cervical dysplasia). Numoda will integrate oversight and logistical functions with the clinical research organizations (CRO), contract laboratories, academic laboratories and statistical groups involved. "The Numoda Corporation offers experience and res that will enable Advaxis to execute multiple high quality clinical trials with precision, efficiency, high quality data and a rapid final study report," commented Advaxis EVP of Science and Operations Dr. John Rothman. Advaxis anticipates that the Numoda Corporation"s involvement will help expedite the clinical trial process. The Company anticipates initiating trial activity in September 2009 as described and delineated in the Company"s most recent 10-Q filing. For more information on public filing documents, please visit the US Security and Exchange Commission"s website at: http://www.sec.gov. Numoda Corporation Advaxis, Incorporated


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009